Adaptimmune settles MD Anderson contract dispute; payment deemed not material

Adaptimmune Therapeutics PLC

Settlement reached on July 16, 2025, with MD Anderson to avoid litigation costs and risks.
MD Anderson had claimed over $21M in damages for breach of 2016 Strategic Alliance Agreement.
Company states payment obligations are not material to its financial position or operations.
All claims will be dismissed upon MD Anderson's receipt of full settlement payment.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.